December 2002
Volume 43, Issue 13
ARVO Annual Meeting Abstract  |   December 2002
Complement Regulatory Proteins Protect the Eye in Autoimmune Uveitis
Author Affiliations & Notes
  • NS Bora
    Ophthalmology & Visual Science Kentucky Lions Eye Center University of Louisville Louisville KY
  • JH Sohn
    Louisville KY
  • HJ Suk
    Louisville KY
  • PS Bora
    Louisville KY
  • HJ Kaplan
    Louisville KY
  • Footnotes
    Commercial Relationships   N.S. Bora, None; J.H. Sohn , None; H.J. Suk , None; P.S. Bora , None; H.J. Kaplan , None. Grant Identification: NIH EY13335, EY09730, EY13094, Grant from RPB, Inc. N.Y. and Commonwealth of Kentucky Research Chall
Investigative Ophthalmology & Visual Science December 2002, Vol.43, 2282. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      NS Bora, JH Sohn, HJ Suk, PS Bora, HJ Kaplan; Complement Regulatory Proteins Protect the Eye in Autoimmune Uveitis . Invest. Ophthalmol. Vis. Sci. 2002;43(13):2282.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Abstract: : Purpose: To explore the role of complement and complement regulatory proteins in experimental autoimmune anterior uveitis (EAAU). Methods: The role of the complement regulatory proteins in EAAU was explored using monoclonal antibodies against rat Crry and CD59. EAAU was induced in two panels of Lewis rats (n=6) by immunization with bovine melanin associated antigen (MAA). In the experimental panel, monoclonal antibody against rat Crry (125ug) or CD59 (250ug) was given on days 9 and 14 post-immunization. Controls were injected with an equal amount of isotype control mouse IgG. Clinical and histopathological examination was used to determine the onset and severity of disease. Lewis rats were sacrificed at three clinical stages of the disease: onset, peak and resolution of ocular inflammation. Results: EAAU started 2 days earlier in antibody injected animals compared to controls. Additionally, the duration of the illness and severity of the disease was dramatically increased in rats treated with monoclonal antibodies for Crry or CD59 compared to controls. The destruction of autologous ocular tissue was also observed in the antibody treated animals; while no damage was observed in the controls. Conclusion: Complement activation is an important component of ocular autoimmunity in EAAU. Furthermore, complement regulatory proteins protect the eye from complement mediated damage during autoimmune uveitis.

Keywords: 612 uveitis-clinical/animal model • 437 inflammation • 435 immunomodulation/immunoregulation 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.